3 completed, 1 active not recruiting, 1 not yet recruiting, 1 recruiting. 5 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 3, Active not recruiting 1, Recruiting 1 |
| Phase 1 | 2 | Completed 1, Recruiting 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow mFOLFOX-6: new trials by email Literature Review of mFOLFOX-6 trials Research Report on mFOLFOX-6
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pre-Operative Treatment in REseCTable COlon CanceR mFOLFOXIRI, mFOLFOX-6, CAPOX - Colo-rectal Cancer, Colon Cancer | Phase 3 | Not yet recruiting | Dominik Paul Modest | 714 | 2025-04-01 | 2025-03-28 |
| Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery Durvalumab, FLOT, mFOLFOX-6 - Esophagus Adenocarcinoma | Phase 2 | Active not recruiting | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 32 | 2023-08-28 | 2026-08-07 |
| FOG-001 in Locally Advanced or Metastatic Solid Tumors FOG-001, mFOLFOX-6, Nivolumab - Cancer, Colorectal Cancer | Phase 1 / Phase 2 | Recruiting | Parabilis Medicines, Inc. | 619 | 2023-05-23 | 2026-10-07 |
| Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib As Firstline Therapy in Her-2 Negative Gastric/GEJ Adenocarcinoma Pembrolizumab, Olaparib, mFOLFOX-6 - Esophagogastric Adenocarcinoma | Phase 2 | Completed | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 31 | 2022-09-15 | 2025-02-20 |
| ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer ABT-888, mFOLFOX-6 - Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Completed | Georgetown University | 64 | 2011-01-03 | 2025-11-06 |
| A Study of Ramucirumab or Icrucumab in Colorectal Cancer Ramucirumab, Icrucumab, mFOLFOX-6 - Colon Cancer, Rectal Cancer | Phase 2 | Completed | Eli Lilly and Company | 158 | 2010-08-01 | 2019-08-06 |
Colonic Neoplasms (2) · Adenocarcinoma (1) · Adenocarcinoma Of Esophagus (1) · Adenomatous Polyposis Coli (1) · Carcinoma, Hepatocellular (1) · Colorectal Neoplasms (1) · Craniopharyngioma (1) · Desmoid Tumors (1) · Endometrial Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms (1) · Rectal Neoplasms (1)
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (2) · Dominik Paul Modest (1) · Eli Lilly and Company (1) · Georgetown University (1) · Parabilis Medicines, Inc. (1)
Germany (3) · United States (3) · Australia (1) · Canada (1)
Salah-Eddin Al-Batran, Prof. Dr. (2) · Benjamin Oshrine (1) · Dominik Modest, Prof. Dr. med. (1) · Georg Martin Haag, PD Dr. (1) · Michael Pishvaian, MD PhD (1)
PMID 27733377, PMID 39956770, PMID 41857556
2023 (1)